NVCT - NASDAQ
Nuvectis Pharma, Inc.
$9.51
-2.1%Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
At a Glance
Live SnapshotNuvectis Pharma, Inc. Management Team
Mr. Ron Bentsur M.B.A.
Co-Founder, Chairman, Chief Executive Officer & President
Compensation
$1,157,639
Mr. Shay Shemesh
Co-Founder, Executive Vice President, Chief Development & Operations Officer
Compensation
$726,713
Dr. Enrique Poradosu Ph.D.
Co-Founder, Executive Vice President, Chief Scientific & Business Officer
Compensation
$726,713
Mr. Michael Carson CPA
Vice President of Finance
Nuvectis Pharma, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.44M worth of NVCT shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
183.8K
1.13M
0
0.00
+1.1M
+$1.13M
9-12 Months
39.0K
314.30K
0
0.00
+314K
+$314K
Top Buyers
Mosseri Marlio Charles
10 Percent Owner
$1.27M
Sanchez Juan
Director
$75K
Kaplan Matthew L.
Director
$64K
Bentsur Ron
Director, 10 Percent Owner, Officer: Chairman & Ceo
$29K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.44M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
NVCT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 16, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.